Successful management of ustekinumab-induced pustular psoriasis without therapy discontinuation

Acta Dermatovenerologica Croatica

Volumn 21, Issue 3, 2013, Pages 202-204

  Caca Biljanovska, Nina ^a   V'lckova Laskoska, Marija ^a   Laskoski, Dimitri ^a  

^a SS CYRIL AND METHODIUS UNIVERSITY   (Macedonia)

Author keywords

Adverse events; Plaque psoriasis; Pustular psoriasis; Ustekinumab

Indexed keywords

CORTICOSTEROID; ETRETIN; METHOTREXATE; PSORALEN; USTEKINUMAB;

ADULT; ARTICLE; CASE REPORT; DISEASE CLEARANCE; DISEASE COURSE; DISEASE SEVERITY; DRUG EFFICACY; DRUG WITHDRAWAL; EPIDERMIS HYPERPLASIA; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HOSPITAL ADMISSION; HUMAN; LIMB; MAINTENANCE THERAPY; PARAKERATOSIS; PSORIASIS VULGARIS; PUSTULAR PSORIASIS; PUSTULE; RASH; REMISSION; SUBCORNEAL PUSTULAR DERMATOSIS; TREATMENT RESPONSE; TRUNK; ULTRAVIOLET A RADIATION;

ADRENAL CORTEX HORMONES; ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; PSORIASIS;

EID: 84886820117     PISSN: 1330027X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (11)

1. Nickoloff BJ. Cracking the cytokine code in psoriasis. Nat Med 2007;13:242-4.
2. Kimball AB, Gordon KB, Langley RG, Menter A, Chatash EK, Valdes J. Safety and efficacy of ABT- 874, a fully human interleukin 12/23 monoclonal antibody, in the treatment of moderate to severe chronic plaque psoriasis: results of a randomized, placebo-controlled, phase 2 trial. Arch Dermatol 2008;144:200-7.
3. Torti DC, Feldman SR. Interleukin-12, interleukin- 23, and psoriasis: current prospects. J Am Acad Dermatol 2007;57:1059-68.
4. Cargill M, Schrodi SJ, Chang M, Garcia VE, Brandon R, Callis KP, et al. A large-scale genetic association study confirms IL12B and leads to the identification of IL23R as psoriasis-risk genes. Am J Hum Genet 2007;80:273-90.
5. Trinchieri G. Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol 2003;3:133-46.
6. Oppmann B, Lesley R, Blom B, Timans JC, Xu Y, Hunte B, et al. Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. Immunity 2000;13:715-25.
7. Yeilding N, Szapary P, Brodmerkel C, Benson J, Plotnick M, Zhou H, et al. Development of the IL- 12/23 antagonist ustekinumab in psoriasis: past, present, and future perspectives. Ann N Y Acad Sci 2011;1222:30-9.
8. Toichi E, Torres G, McCormick TS, Chang T, Mascelli MA, Kauffman CL, et al. An anti-IL-12p40 antibody down-regulates type 1 cytokines, chemokines, and IL-12/IL-23 in psoriasis. J Immunol 2006;177:4917-26.
9. Wenk KS, Claros JM, Ehrlich A. Flare of pustular psoriasis after initiating ustekinumab therapy. J Dermatol Treat 2012;23:212-4.
10. Gregoriou S, Kazakos C, Christofidou E, Kontochristopoulos G, Vakis G, Rigopoulos D. Pustular psoriasis development after initial ustekinumab administration in chronic plaque psoriasis. Eur J Dermatol 2011;21:104-5.
11. Papp KA, Langley RG, Lebwohl M, Krueger G, Szzapary P, Yeilding N, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52- week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet 2008;371(9625):1675-84.